Driven by strong organic growth, an in-licensing agreement with Sanofi, the consolidation of Mantra, and the resolution of most legal challenges, Emcure is projected to achieve a 13% overall sales CAGR between FY2024 and FY2027. Enhanced productivity following a 20%+ expansion in field force since FY2022, along with increased utilisation of new facilities, is expected to contribute to robust EBITDA and EPS CAGRs of 18% and 29%, respectively, during the same period.
Emcure Pharma shares advance 10% as Kotak Equities sees 28% upside in stock
Date:
More like thisRelated
How Symmetry Works—and Why It Is Already Part of Our Law
As my last post explained, my new book, Constitutional...
“What Is Government Itself, but the Greatest of All Reflections of Human Nature?”
That's a famous line in Federalist No. 51, generally...
See the best Black Friday TV deals from Amazon, Best Buy, and Walmart
The best Black Friday TV deals from Amazon, Best...